Answers are grounded in this paper and cite their sources.
Biofilms on implanted devices tolerate antibiotics and host defences, and established device infection is usually treated by removing the device. This review examines the clinical trial record across nine implanted-device settings. A consistent asymmetry emerges: every intervention that has reached approval or guideline endorsement prevents biofilm formation on an uninfected device by delivering an antimicrobial locally in a high-risk population, whereas attempts to eradicate established biofilm remain conflicting or uncontrolled. Trials that failed did so largely for reasons unrelated to antibiofilm pharmacology, including endpoints measuring colonisation rather than disease, extrapolation from animal models, event rates too low for feasible sample sizes, manufacturing instability and sponsor insolvency. Silver illustrates the problem, showing consistent laboratory activity but no benefit in adequately powered trials. The principal obstacle may therefore be the design of trials rather than the discovery of new molecules.
No takes yet. Share an insight, caveat, or question.
Sayed Mahmood Alqallaf (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: